Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals develops, manufactures, and sells medicines for various diseases worldwide. Products include EYLEA for eye conditions, Dupixent for atopic dermatitis and asthma, Libtayo for cutaneous squamous cell carcinoma, Praluent for hypercholesterolemia and cardiovascular disease, REGEN-COV for COVID-19, Kevzara for rheumatoid arthritis, Inmazeb for ebolavirus infection, ARCALYST for cryopyrin-associated periodic syndromes, and ZALTRAP for metastatic colorectal cancer.
Overview
Strengths
- Current Price to Earnings Ratio (17.25) is lower than the sector mean (91.15).
- Price to book ratio (2.49) is lower than the sector mean (24.44).
- Earnings are projected to grow at a solid rate (10.5% per year).
- The company has low debt. Net Debt to EBITDA Ratio is -0.08 and it is lower than the sector mean.
- The company has high returns. ROIC (14.66%) is higher than the sector mean (6.02%).
- EV/EBIT (14.66) is lower than the sector mean.
- Price to free cash flow (20.64) is lower than the sector mean.
- Strong EBITDA Margin of 36.63%.
Weaknesses
- With a depreciation Potential of -22.44%, based on our fundamental analysis, it suggests the stock may be overvalued.
Key Financial Data